Bradykinin B2 receptor null mice harboring a Ser 23-to-Ala substitution in the p53 gene are protected from renal dysgenesis

American Journal of Physiology - Renal Physiology

Volumn 295, Issue 5, 2008, Pages

  El Dahr, Samir S ^a,b   Aboudehen, Karam ^a   Dipp, Susana ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Gene knockin; Gene knockout; Kidney development; Nephrogenesis

Indexed keywords

ALANINE; AQUAPORIN 2; BICARBONATE SODIUM COTRANSPORTER; BRADYKININ B2 RECEPTOR; PROTEIN P53; SERINE; SODIUM CHLORIDE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; TUMOR SUPPRESSOR PROTEIN; SLC5A1 PROTEIN, MOUSE; SODIUM CHLORIDE; SODIUM POTASSIUM CHLORIDE COTRANSPORTER 2 PROTEIN; SODIUM-POTASSIUM CHLORIDE COTRANSPORTER 2 PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; KIDNEY DEVELOPMENT; KIDNEY DYSGENESIS; KIDNEY MALFORMATION; KNOCKOUT MOUSE; MOUSE; MOUSE MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WILD TYPE; ANIMAL; ANIMAL EMBRYO; C57BL MOUSE; CONGENITAL DISORDER; CONGENITAL MALFORMATION; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; MALE; METABOLISM; NEWBORN; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PREGNANCY; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; AMINO ACID SUBSTITUTION; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; AQUAPORIN 2; CONGENITAL ABNORMALITIES; EMBRYO, MAMMALIAN; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PHOSPHORYLATION; PREGNANCY; RECEPTOR, BRADYKININ B2; SODIUM CHLORIDE; SODIUM CHLORIDE SYMPORTERS; SODIUM-BICARBONATE SYMPORTERS; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-POTASSIUM-CHLORIDE SYMPORTERS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 57349174499     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90378.2008     Document Type: Article

References (45)

1. Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension 29: 483-487, 1997.
2. Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224: 625-630, 1996.
3. Alric C, Pecher C, Schanstra JP, Bascands JL, Girolami JP. Bradykinin-induced inhibition of cell proliferation and tyrosine kinase activity in rat mesangial cells. Int J Mol Med 5: 85-93, 2000.
4. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 20: 3224-3233, 2000.
5. Ashcroft M, Vousden KH. Regulation of p53 stability. Oncogene 18: 7637-7643, 1999.
6. Baricos WH, Cortez SL, El-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int 47: 1039-1047, 1995.
7. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3: 421-429, 2003.
8. Bates CM. Kidney development: regulatory molecules crucial to both mice and men. Mol Genet Metab 71: 391-396, 2000.
9. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 4: 793-805, 2004.
10. Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, Hess JF. Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem 270: 13706-13710, 1995.
11. Cervenka L, Harrison-Bernard LM, Dipp S, Primrose G, Imig JD, El-Dahr SS. Early onset salt-sensitive hypertension in bradykinin B2 receptor null mice. Hypertension 34: 176-180, 1999.
12. Chao C, Herr D, Chun J, Xu Y. Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J 25: 2615-2622, 2006.
13. Chao C, Madeddu P, Wang C, Liang Y, Chao L, Chao J. Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. Am J Physiol Renal Fluid Electrolyte Physiol 271: F78-F86, 1996.
14. Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA 96: 13777-13782, 1999.
15. El-Dahr SS. Spatial expression of the kallikrein-kinin system during nephrogenesis. Histol Histopathol 19: 1301-1310, 2004.
16. El-Dahr SS, Chao J. Spatial and temporal expression of kallikrein and its mRNA during nephron maturation. Am J Physiol Renal Fluid Electrolyte Physiol 262: F705-F711, 1992.
17. El-Dahr SS, Dipp S, Baricos WH. Bradykinin stimulates the ERK→Elk-1→Fos/AP-1 pathway in mesangial cells. Am J Physiol Renal Physiol 275: F343-F352, 1998.
18. El-Dahr SS, Dipp S, Meleg-Smith S, Pinna-Parpaglia P, Madeddu P. Fetal ontogeny and role of metanephric bradykinin B2 receptors. Pediatr Nephrol 14: 288-296, 2000.
19. El-Dahr SS, Dipp S, Yosipiv IV, Carbini LA. Activation of kininogen expression during distal nephron differentiation. Am J Physiol Renal Physiol 275: F173-F182, 1998.
20. El-Dahr SS, Figueroa CD, Gonzalez CB, Muller-Esterl W. Ontogeny of bradykinin B2 receptors in the rat kidney: implications for segmental nephron maturation. Kidney Int 51: 739-749, 1997.
21. 2 null mice are prone to renal dysplasia: gene-environment interactions in kidney development. Physiol Genomics 3: 121-131, 2000.
22. Fan H, Harrell JR, Dipp S, Saifudeen Z, El-Dahr SS. A novel pathological role of p53 in kidney development revealed by gene-environment interactions. Am J Physiol Renal Physiol 288: F98-F107, 2005.
23. Fan H, Harrell JR, Dipp S, Saifudeen Z, El-Dahr SS. A novel pathological role of p53 in kidney development revealed by gene-environment interactions. Am J Physiol Renal Physiol 288: F98-F107, 2005.
24. Fan H, Stefkova J, El-Dahr SS. Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway. Am J Physiol Renal Physiol 291: F670-F682, 2006.
25. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene 17: 2543-2547, 1998.
26. Gattone VH 2nd, Maser RL, Tina C, Rosenberg JM, Brandon MG. Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease. Dev Genet 24: 309-318, 1999.
27. CRD mice. Am J Physiol Regul Integr Comp Physiol 285: R782-R790, 2003.
28. Hu MC, Resemble ND. Genetic regulation of branching morphogenesis: lessons learned from loss-of-function phenotypes. Pediatr Res 54: 433-438, 2003.
29. Kari S, Sakaguchi K, Shimohigashi Y, Samaddar S, Banerjee R, Basu G, Swaminathan V, Kundu TK, Roy S. Effect of phosphorylation on the structure and fold of transactivation domain of p53. J Biol Chem 277: 15579-15585, 2002.
30. Knights CD, Catania J, Giovanni SD, Muratoglu S, Perez R, Swartzbeck A, Quong AA, Zhang X, Beerman T, Pestell RG, Avantaggiati ML. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 173: 533-544, 2006.
31. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 387: 299-303, 1997.
32. Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene 18: 7644-7655, 1999.
33. Lechner MS, Dressler GR. The molecular basis of embryonic kidney development. Mech Dev 62: 105-120, 1997.
34. Lozano G, Montes de Oca Luna R. MDM2 function. Biochim Biophys Acta 1377: M55-M59, 1998.
35. MacPherson D, Kim J, Kim T, Rhee BK, Van Oostrom CT, DiTullio RA, Venere M, Halazonetis TD, Bronson R, De Vries A, Fleming M, Jacks T. Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J 23: 3689-3699, 2004.
36. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, Dessi-Fulgheri P, Sarzani R, Anania V. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. Circulation 96: 3570-3578, 1997.
37. Marks J, Saifudeen Z, Dipp S, El-Dahr SS. Two functionally divergent p53-responsive elements in the rat bradykinin B2 receptor promoter. J Biol Chem 278: 34158-34166, 2003.
38. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, Donner DB. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 280: 25953-25959, 2005.
39. Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res 1: 1001-1008, 2003.
40. Putnam WC, Swenson SM, Reif GA, Wallace DP, Helmkamp GM Jr, Grantham JJ. Identification of a forskolin-like molecule in human renal cysts. J Am Soc Nephrol 18: 934-943, 2007.
41. Saifudeen Z, Dipp S, Fan H, El-Dahr SS. Combinatorial control of the bradykinin B2 receptor promoter by p53, CREB, KLF-4, and CBP: implications for terminal nephron differentiation. Am J Physiol Renal Physiol 288: F899-F909, 2005.
42. Saifudeen Z, Du H, Dipp S, El-Dahr SS. The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. J Biol Chem 275: 15557-15562, 2000.
43. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14: 289-300, 2000.
44. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2: 40-55; quiz 55, 2006.
45. Vainio S, Lin Y. Coordinating early kidney development: lessons from gene targeting. Nat Rev Genet 3: 533-543, 2002.